1. Scrip
  2. >>R&D

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

Mutation-Agnostic Treatment Advances

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Cancer Cells
Aptose reports promising results for triplet therapy for mutation-agnostic frontline AML. (Shutterstock)

New data from Aptose Biosciences’ Phase I/II TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) show patients receiving 40mg or 80mg of the once-daily, oral multi-kinase inhibitor tuspetinib (licensed from South Korea’s Hanmi Pharm) in combination with standard of care doses of venetoclax and azacitidine demonstrated promising activity and safety.

The triple therapy is being developed by the Toronto, Canada-based firm as a mutation-agnostic frontline treatment for newly diagnosed AML...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Therapy Areas

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 
• By Andrew McConaghie

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?